DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced the development of a pediatric circulatory support technology. Currently in pre-clinical studies, Abiomed has developed a catheter-based heart pump, similar to the Impella LP2.5, which provides left-ventricular support to small pediatric patients requiring preconditioning prior to a cardiac intervention, or to recover patients who are either post-surgery, cannot be weaned from bypass, or who have endocarditis. The technology has been designed to operate as either a pulsatile device that can provide up to 120 beats per minute or as a continuous flow technology, and is estimated to provide circulatory support for approximately two weeks.
